TG Therapeutics (TGTX) is trading higher as investors react to a fresh catalyst tied to BRIUMVI’s clinical and real‑world evidence narrative ahead of the American Academy of Neurology (AAN) 2026 annual meeting. The company recently detailed a schedule of BRIUMVI presentations for the meeting, keeping attention on durability, safety, and treatment-experience messaging that can influence prescribing momentum in relapsing forms of multiple sclerosis. (ir.tgtherapeutics.com)

Beyond the scientific-newsflow setup, TGTX has had supportive capital-allocation headlines in the background. The board authorized an increase in the share repurchase program to $300 million (from $100 million), reinforcing the message that management views the stock as undervalued relative to cash-generation potential from BRIUMVI. (benzinga.com)

Separately, TG Therapeutics refinanced with a new $750 million term loan facility maturing March 18, 2031, and also put in place an additional uncommitted facility of up to $250 million—steps that can reduce near-term balance-sheet pressure while maintaining flexibility for commercial execution and shareholder returns. (sec.gov)

Near term, traders will focus on whether AAN 2026 readouts and real-world updates reinforce the product’s differentiation and sustain demand growth into mid-2026. In parallel, investors will watch the pace and pricing of repurchases under the expanded authorization and any follow-through disclosures on capital structure after the term-loan transaction, since both can materially shape per-share outcomes even without a change in revenue guidance. (ir.tgtherapeutics.com)